BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BC Extra | Nov 12, 2014
Company News

Ascletis gets China license for Presidio HCV candidate

Presidio Pharmaceuticals Inc. (San Francisco, Calif.) granted Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) exclusive development and commercialization rights to HCV candidate PPI-668 in China, Taiwan, Hong Kong and Macau. Presidio received an undisclosed upfront payment...
BC Week In Review | May 6, 2013
Company News

Ascletis, J&J deal

Johnson & Johnson's Janssen R&D Ireland unit granted Ascletis exclusive rights to develop and commercialize Janssen's HIV compound TMC310911 in China. J&J is eligible for undisclosed royalties based on Chinese sales of the HIV protease...
BC Extra | May 1, 2013
Company News

J&J grants Ascletis Chinese rights to HIV candidate

The Janssen R&D Ireland unit of Johnson & Johnson (NYSE:JNJ) granted Ascletis Pharmaceuticals Co. Ltd. (Hangzhou, China) exclusive, Chinese rights to develop and commercialize Janssen's HIV compound TMC310911. J&J is eligible for undisclosed royalties based...
Items per page:
1 - 4 of 4